Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of radiotherapy with anlotinib and sintilimab in driver gene-negative unresectable locally advanced non-small cell lung cancer after failure of chemoradiation
ChiCTR2100042143Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and sintilimab in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100042143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042143.